- 2019 (24) ▼
- 2018 (21) ▼
- 2017 (10) ▼
- 2016 (15) ▼
We are pleased to announce that the LSD Support Society of India has joined the EGA as an associate member.
A seminar for young adult Gaucher patients
The EGA is organising an event for young adult Gaucher patients from all member associations, …
We are pleased to announce that Mexico has joined the EGA as an associate member.
We are pleased to announce that Bosnia & Herzegovina joined the EGA as full member.
FDA approves new orphan drug to treat a form of Gaucher disease (01.05.2012)
The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare …
We are pleased to announce that Macedonia and Switzerland joined the EGA as full members.
...and will continue to be a priority in the future, we have pledged to help any Gaucher patient who ask us for help where ever they live. However the “Gaucher-world” has …
Shire Announces European Approval of Manufacturing Facility for VPRIV® (velaglucerase alfa)
European Medicines Agency Approval Adds Significant Capacity for the Manufacture of Shire’s Enzyme Replacement Therapies
Lexington, MA, US …
Together with the organising committee of the 10th EWGGD Meeting we are delighted to provide you with more information about the next meeting.
This year’s meeting will be held from June 28th to 30th, 2012 at the Novotel Paris Tour Eiffel in …
Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the …